These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37380347)

  • 21. Kidney and heart failure outcomes associated with SGLT2 inhibitor use.
    van der Aart-van der Beek AB; de Boer RA; Heerspink HJL
    Nat Rev Nephrol; 2022 May; 18(5):294-306. PubMed ID: 35145275
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
    Nana M; Morgan H; Bondugulapati LNR
    Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes.
    Singhal R; Hechanova LA
    Curr Cardiol Rep; 2022 Mar; 24(3):183-189. PubMed ID: 35147891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Renal effects of sodium-glucose cotransporter 2 inhibitors in patients with cardiovascular disease with and without chronic kidney disease].
    Benvenuto M; Panzarella G; Shehaj E; Valenti C; Caldarola P; Colivicchi F; Gabrielli D; Iacoviello M;
    G Ital Cardiol (Rome); 2023 Mar; 24(3):188-195. PubMed ID: 36853155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 Inhibitors: A New Therapeutical Strategy to Improve Clinical Outcomes in Patients with Chronic Kidney Diseases.
    Di Costanzo A; Esposito G; Indolfi C; Spaccarotella CAM
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines.
    Gongora CA; Drobni ZD; Quinaglia Araujo Costa Silva T; Zafar A; Gong J; Zlotoff DA; Gilman HK; Hartmann SE; Sama S; Nikolaidou S; Suero-Abreu GA; Jacobsen E; Abramson JS; Hochberg E; Barnes J; Armand P; Thavendiranathan P; Nohria A; Neilan TG
    JACC Heart Fail; 2022 Aug; 10(8):559-567. PubMed ID: 35902159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal Effects of Sodium-Glucose Co-Transporter Inhibitors.
    Thomson SC; Vallon V
    Am J Cardiol; 2019 Dec; 124 Suppl 1(Suppl 1):S28-S35. PubMed ID: 31741437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
    Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
    Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of sodium-glucose co-transporter 2 protein inhibitors in heart failure: more than an antidiabetic drug?
    Savarimuthu S; Harky A
    Expert Opin Pharmacother; 2022 Feb; 23(3):377-386. PubMed ID: 34713764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
    Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
    Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of sodium-glucose cotransporter 2 to slow the progression of chronic kidney disease.
    Oguz F; Demoulin N; Thissen JP; Jadoul M; Morelle J
    Acta Clin Belg; 2022 Aug; 77(4):805-814. PubMed ID: 34404335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease.
    Scheen AJ; Delanaye P
    Expert Rev Endocrinol Metab; 2022 Jan; 17(1):35-46. PubMed ID: 34908510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease.
    Mima A
    Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies.
    Hinton W; Ansari AS; Whyte MB; McGovern AP; Feher MD; Munro N; de Lusignan S
    Diabetes Obes Metab; 2023 Feb; 25(2):501-515. PubMed ID: 36239122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhang M; Zhou HR
    Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
    Bailey CJ; Day C; Bellary S
    Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.